



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan R. Fritzberg

Title: THERAPEUTIC AND DIAGNOSTIC COMPOUNDS, COMPOSITIONS, AND METHODS

Docket No.: 295.034US1

Serial No.: 10/615484

Filed: July 8, 2003

Due Date: N/A

Examiner: Unknown

Group Art Unit: 1614

Customer No.: 21186

Confirmation No.: 8966


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):


- ☒ A return postcard.
- ☒ A Supplemental Information Disclosure Statement (1 pg.), Form 1449 (10 pgs.), and copies of 155 cited documents.
- ☒ Communication concerning Related Application(s) (1 pg.).

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
Customer Number 21186

By: 
Atty: Robert J. Harris
Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 29th day of December, 2003.


Name


Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. Customer Number 21186
(GENERAL)

S/N 10/615484

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan R. Fritzberg
Serial No.: 10/615484
Filed: July 8, 2003
Title: THERAPEUTIC AND DIAGNOSTIC COMPOUNDS, COMPOSITIONS, AND METHODS

Examiner: Unknown
Group Art Unit: 1614
Docket: 295.034US1

(Circular stamp: RECEIVED JAN 02 2004 TRADEMARK OFFICE)

COMMUNICATION CONCERNING RELATED APPLICATION(S)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant would like to bring to the Examiner's attention the following related copending applications in the above-identified patent application:


<u>Serial/Patent No.</u>	<u>Filing Date</u>	<u>Attorney Docket</u>	<u>Title</u>
10/014335	December 11, 2001	295.044US1	HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION
10/159245	May 29, 2002	295.044US2	HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION
10/601081	June 20, 2003	295.054US1	SKELETAL-TARGETED RADIATION TO TREAT BONE-ASSOCIATED PATHOLOGIES

Respectfully submitted,
ALAN R. FRITZBERG
By Applicant's Representatives,


SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 359-3265


Date 12-29-03

By


Robert J. Harris
Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 29th day of December, 2003.


Name


Signature



S/N 10/615484

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Alan R. Fritzberg	Examiner:	Unknown
Serial No.:	10/615484	Group Art Unit:	1614
Filed:	July 08, 2003	Docket:	295.034US1
Title:	THERAPEUTIC AND DIAGNOSTIC COMPOUNDS, COMPOSITIONS, AND METHODS		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), no fee is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.


Respectfully submitted,
ALAN R. FRITZBERG
By his Representatives,


SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 359-3265

Date 12-29-03

By 
Robert J. Harris
Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 29th day of December, 2003.


Name



Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Applicati n Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1614
Examiner Name	Unknown

Sheet 1 of 10

Attorney Docket No: 295.034US1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Date				Translation
	CA 1,078,731	06/03/1980				
	EP 0 164 843	12/18/1985				
	EP 0 210 043	01/28/1987				
	EP 0 232 751	08/19/1987				
	EP 0 255 471	02/03/1988				English Abstract
	EP 0 258 616	03/09/1988				
	EP 0 287 465	10/19/1988				English Abstract
	EP 0 374 501	06/27/1990				
	EP 0 382 582	08/16/1990				
	EP 0 408 701	01/23/1991				
	EP 0 411 941	02/06/1991				
	EP 0 455 380	11/06/1991				
	EP 0 698 029	02/28/1996				
	EP 0 972 528	01/19/2000				English Abstract
	FR 2 230 374	12/20/1974				English Abstract
	WO 84/03698	09/27/1984				
	WO 90/06776	06/28/1990				
	WO 91/16075	10/31/1991				
	WO 93/25240	12/23/1993				
	WO 94/26753	11/24/1994				
	WO 95/10940	04/27/1995				
	WO 00/76556	12/21/2000				
	WO 01/91806	12/06/2001				

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1614
Examiner Name	Unknown

Sheet 2 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTSExaminer
Initials*

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

"Bone Cancer Therapy Project Funding Awarded to Brookhaven National Laboratory for Diatide-Licensed Product", DISTRIBUTION: Business Editors and Health/Medical Writers (1999).

"Breast Cancer; Genitourinary Cancer; Multiple Myeloma", Annotated Guide to Cancer Chemotherapeutic Regimens 1999/2000, Oncology Special Edition, 13-14; 17-18; 32."Chapter III: Chemotherapy Regimens in Adults", In Cancer Chemotherapy Pocket Guide, Robert J. Ignoffo, Editor, 248-255; 338-341 (1998)."Multiple Myeloma", In Clinical Oncology. A Multidisciplinary Approach for Physicians and Students, 7th Edition, Philip Rubin, Editor, 239-244 (1993)."NeoRx Updates Skeletal Targeted Radiotherapy (STR) Phase I/II Trial Data", NeoRx Press Release, (2001)."NeoRx's Multiple Myeloma Study with Targeted Radiotherapy to be Updated at ASH -- Recent Thalidomide Results Heighten Interest in New Multiple Myeloma Therapies", NeoRx Press Release, (1999)."NeoRx's Targeted Radiotherapy Achieves Complete Responses with Excellent Safety in Multiple Myeloma Patients", NeoRx Press Release, (1999)."Phase I/II Interim Data on NeoRx's STR Product in Multiple Myeloma", NeoRx Press Release, (1999).

ABRAMS, "High-Dose Targeted Radiation to Bone and Bone Metastases", CaP CURE Meeting, Lake Tahoe, NV (2000).

ALEXANIAN et al., "Impact of Complete Remission with Intensive Therapy in Patients with Responsive Multiple Myeloma", British Journal of Hematology, 27, 1037-1043 (2001).ANDERSON et al., "High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients with Osteosarcoma and Bone Metastases", Journal of Clinical Oncology, 20, 189-196 (2002).ANDO et al., "177Lu-EDTMP: A Potential Therapeutic Bone Agent", Nucl. Med. Commun., 19, 587-591 (1998).APPELBAUM et al., "Chronic and Acute Leukemias in Adults", The Role of Marrow Transplantation in the Treatment of Leukemia, Martinus Nijhoff Publishers, Boston. C.D. Bloomfield, editor, 229-262 (1985).APPELBAUM et al., "Specific Marrow Ablation Before Marrow Transplantation Using an Aminophosphonic Acid Conjugate 166Ho-EDTMP", Blood, 80, 1608-1613 (1992).BARDIES et al., "Computational Methods in Radionuclide Dosimetry", Physics in Medicine and Biology, 41, 1941-1955 (1996).BARLOGIE et al., "Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.", Blood, 72, 2015-2019 (1988).BATAILLE et al., "Multiple Myeloma", New England Journal of Medicine, 336, 1657-1664 (1997).BAYOUTH et al., "Dosimetry Considerations of Bone-Seeking Radionuclides for Marrow Ablation", Medical Physics, 20, 1089-1096 (1993).BAYOUTH et al., "Pharmacokinetics, Dosimetry and Toxicity of Holmium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma", The Journal of Nuclear Medicine, 36, 730-737 (1995).BAYOUTH et al., "Radiation Dose Distribution Within the Bone Marrow of Patients Receiving Holmium-166-Labeled-Phosphonate for Marrow Ablation", Medical Physics, 22, 743-753 (1995).

EXAMINER

DATE CONSIDERED


Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Applicant Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1614
Examiner Name	Unknown

Sheet 3 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BEARMAN et al., "Regimen-related Toxicity in Patients Undergoing Bone Marrow Transplantation", <u>Journal of Clinical Oncology</u> , <u>6</u> , 1562-1568 (1988).
	BEDDOE et al., "Measurements of Trabecular Bone Structure in Man", <u>Physics in Medicine and Biology</u> , <u>21</u> , 589-607 (1976).
	BENSINGER et al., "166Holmium-DOTMP Plus Standard High Dose Chemotherapy (HDC) with Autologous Transplant Produce High Rates of Complete Remission (CR) in Multiple Myeloma (MM) Patients: An Updated Report of a Phase I/II Study", <u>Proceedings of the American Society of Clinical Oncology</u> , <u>20</u> , Abstract No. 18, 5a (2001).
	BENSINGER et al., "Phase I/II Study of 166Holmium-DOTMP in Combination with Melphalan +/- Total Body Irradiation (TBI) with Autologous Peripheral Blood Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>Proceedings of the American Society of Clinical Oncology 2000</u> , <u>19</u> , Abstract No. 26, 9a (2000).
	BENSINGER et al., "166Ho-DOTMP and High-Dose Melphalan before Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma", Abstract P287; IXth International Workshop on Multiple Myeloma (2003).
	BENSINGER et al., "Skeletal Targeted Radiotherapy (STR) with 166Ho-DOTMP plus Melphalan and Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma(MM)", <u>Meeting Proceedings of ASCO</u> , <u>22</u> , ASCO Annual Meeting, May 2003; Abstract Number 3346, 833 (2003).
	BIGLER et al., "Skeletal Distribution of Mineralized Bone Tissue in Humans", <u>Health Physics</u> , <u>31</u> , 213-218 (1976).
	BOUSSOTIS et al., "Bone Marrow Transplantation for Low-grade Lymphoma and Chronic Lymphocytic Leukemia", <u>Semin Hematol</u> , <u>36</u> , 209-216 (1999).
	BREITZ, "Dosimetry in a Myeloablative Setting", Annual Society of Nuclear Medicine Meeting, Continuing Education Course (2001).
	BREITZ et al., "Dosimetry in Myeloblastic Setting", <u>Cancer Biother. Radiopharm.</u> , <u>17</u> , 119-128 (2002).
	BREITZ et al., "Dosimetry of High Dose Skeletal Targeted Radiotherapy with Ho-166 DOTMP", Presentation at VIIth International Radiopharmaceutical Dosimetry Symposium (2002).
	BREITZ et al., "Multiple Myeloma: Skeletal Targeted Radiotherapy with 166-Ho-DOTMP for Treatment of Multiple Myeloma", Presented at "Targeted Radionuclide Therapy" (2002).
	BREITZ, "Quantitative Dosimetry Workup in a Myeloablative Setting", Presentation at the 48th Annual Society for Nuclear Medicine Meeting (2001).
	BREITZ et al., "Dosimetry of High Dose Skeletal Targeted Radiotherapy (STR) with 166-Ho-DOTMP", <u>Cancer Biotherapy and Radiopharmaceuticals</u> , <u>18</u> , 225-230 (2003).
	CHAMPLIN et al., "166Holmium-DOTMP in Combination with Melphalan with or without Total Body Irradiation as a Preparative Regimen for Autologous Stem Cell Transplant (ASCT) for Patients with Multiple Myeloma (MM)", <u>Blood</u> , <u>94</u> (10), American Society of Hematology, Abstract No. 3133, 709a (1999).
	CHAMPLIN et al., "Bone Marrow Transplantation for Acute Leukemia: Recent Advances and Comparison with Alternative Therapies", <u>Seminars in Hematology</u> , <u>24</u> , 55-67 (1987).

EXAMINER

DATE CONSIDERED


Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Applicati n Number	10/615,484
Filing Dat	July 08, 2003
First Named Inventor	Fritzberg, Alan
Gr up Art Unit	1614
Examiner Name	Unknown

Sheet 4 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CHAMPLIN et al., "Holmium-166 DOTMP, A Bone Seeking Radiochelate for Selective Marrow Radiotherapy with Bone Marrow Transplantation (BMT) for Multiple Myeloma", <u>Experimental Hematology</u> , 21, Abstracts, 22nd Annual Meeting of the International Society for Experimental Hematology, Rotterdam, The Netherlands, Abstract No. 393, 1117 (1993).
	CHAMPLIN et al., "Holmium-166 DOTMP, A Bone Seeking Radiochelate For Selective Marrow Radiotherapy with Bone Marrow Transplantation (BMT) for Multiple Myeloma", <u>Blood</u> , 82, Abstracts, American Society of Hematology Thirty-Fifth Annual Meeting, St. Louis, MO, Abstract No. 1051, 266a (1993).
	CHAMPLIN et al., "Phase I/II Study of Targeted Radiotherapy Using 166Ho-DOTMP with Melphalan and Peripheral Blood Stem Cell Transplant for Multiple Myeloma", A slide presentation, International Society of Experimental Hematology (2000).
	CHAMPLIN et al., "Role of Bone Marrow Transplantation in the Treatment of Hematologic Malignancies and Solid Tumors: Critical Review of Syngeneic, Autologous, and Allogeneic Transplants.", <u>Cancer Treatment Reports</u> , 68, 145-161 (1984).
	CHAMPLIN, R. , et al., "Two Phase I/II Studies of 166Holmium-DOTMP in Combination with Melphalan With or Without Total Body Irradiation as a Preparative Regimen for Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>Experimental Hematology</u> , 27(7), Abstract No. 196, Program and Abstracts, 28th Annual Meeting of the International Society for Experimental Hematology, Monte Carlo, Monaco, 88 (1999).
	CLEYNHENS et al., " ^{99m} Tc-EC-AMDP, a Bone Agent with Rapid Clearance from Soft Tissue", <u>Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine</u> , 5, 605-609 (1999).
	COHEN et al., "Bisphosphonates and Tetracycline: Experimental Models for Their Evaluation in Calcium-Related Disorders", <u>Pharmaceutical Research</u> , 15, 606-613 (1998).
	CUNNINGHAM et al., "High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data", <u>Journal of Clinical Oncology</u> , 12, 764-768 (1994).
	DISPENZIERI et al., "A Phase I Study of a Conditioning Regimen for Peripheral Stem Cell Transplantation (PBSCT) for Multiple Myeloma (MM): 153Samarium Ethylenediaminetetramethylenephosphonate (153SM-EDMPT) and Melphalan", <u>Blood</u> , 96, Abstract 2397, 558a (2000).
	DISPENZIERI et al., "A Phase I/II Dose Escalation Study of 153-Samarium EDTMP (153-Sm-EDMTP) with Fixed Dose Melphalan Peripheral Stem Cell Transplantation (PBSCT) for Multiple Myeloma (MM)", <u>Blood</u> , 98, Abstract 2855, 682a-683a (2001).
	DURRANT et al., "Sm-153 Lexidronam, Limb Irradiation and Stem Cell Transplantation for the Treatment of Multiple Myeloma", Amer. Soc. Hemeotology Annual Meeting, Orlando, FL. (2001).
	EARY et al., "Samarium-153-EDTMP Biodistribution and Dosimetry Estimation", <u>The Journal of Nuclear Medicine</u> , 34, 1031-1036 (1993).
	ECKERMAN et al., "Dose Conversion Factors for Marrow and Bone by Skeletal Regions", <u>Journal of Nucler Medicine</u> , 35, 112P (1994).
	EISENHUT, M , "Iodine-131-Labeled Diphosphonates for the Palliative Treatment of Bone Metastases: I. Organ Distribution and Kinetics of I-131 BDP3 in Rats", <u>The Journal of Nuclear Medicine</u> , 25, 1356-1361 (1984).

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Applicati n Number	10/615,484
Filing Dat	July 08, 2003
Fir t Named Inv nt r	Fritzberg, Alan
Group Art Unit	1614
Examiner Name	Unknown

Sheet 5 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	EISENHUT et al., "The Influence of Substituents in ^{99m} Tc-Benzylidenediphosphonate Complexes on their Organ Distribution in Rats", <u>Nuklearmedizin</u> , 23 , 119-122 (1984).
	FIRUSIAN et al., "Results of 89Strontium Therapy in Patients with Carcinoma of the Prostate and Incurable Pain from Bone Metastases: A Preliminary Report", <u>The Journal of Urology</u> , 116 , 764-768 (1976).
	FRITZBERG, "Holmium-166 DOTMP for Marrow Ablation: Clinical Studies to Demonstrate Efficacy in Multiple Myeloma", Society of Nuclear Medicine Annual Meeting, St. Louis (2000).
	FUJISAKI et al., "Physicochemical Characterization of Bisphosphonic Carboxyfluorescein for Osteotropic Drug Delivery", <u>J Pharm Pharmacol.</u> , 48 , 798-800 (1996).
	GARLICH et al., "Chemical Considerations of 153Sm-EDTMP, a New Therapeutic Bone Agent", Sixth International Symposium on Radiopharmaceutical Chemistry: Abstracts. Boston, June 29-July 3, 1986. Paper 140, 317-319 (1986).
	GARLICH et al., "Chemistry of Novel Macrocyclic Aminophosphonic Acid Chelates of Rare Earth Radionuclides and Their in vivo Biodistribution", <u>The Journal of Nuclear Medicine</u> , 34 , Abstract Book, Proceedings of the 40th Annual Meeting, Toronto, Ontario, Canada, Abstract No. 1134, 244P (1993).
	GERALDES et al., "Synthesis, Protonation Sequence, and NMR Studies of Polyazamacrocyclic Methylene phosphonates", <u>Inorganic Chemistry</u> , 28 , 3336-3341 (1989).
	GIRALT et al., "Hemorrhagic Cystitis after Targeted Radiotherapy with Holmium-DOTMP (166Ho) for Multiple Myeloma (MM) is Preventable with Bladder Irrigation", <u>Blood</u> , 96 (11), Abstract No. 1686 (2000).
	GIRALT et al., "Preliminary Results of a Phase I/II Study of Multiple Myeloma (MM) Patients Treated with 166Holmium-DOTMP in Combination with High Dose Melphalan +/- Total Body Irradiation (TBI) with Autologous Stem Cell Transplant (ASCT)", <u>Blood</u> , 96 (11), Abstract No. 2395 (2000).
	GIRALT et al., "Results of a Phase I/II Trial with 166Ho-DOTMP Plus High Dose Chemotherapy in Patients with Multiple Myeloma", <u>VIIIth Int'l Multiple Myeloma Proceedings</u> , Abstract No. S24, 40-41 (2001).
	GIRALT et al., "Two Phase I/II Studies of 166Holmium-DOTMP in Combination with or without TBI as a Preparative Regimen for Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>VIIth Int'l Multiple Myeloma Workshop</u> , Abstract No. 033, Meeting Held September 1-5, 1999, 117 (1999).
	GIRALT et al., "166Ho-DOTMP Plus Melphalan Followed by Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma: Results of Two Phase I/II Trials", <u>Blood</u> , Blood First Edition Paper; DOI 10.1182/2002-10-3250, 1-38 (2003).
	GIRALT et al., "Long-Term Follow-Up of 83 Patients with Multiple Myeloma (MM) Treated on a Phase I-II Study of Skeletal Targeted Radiotherapy (STR) Using 166Ho-DOTMP Plus Melphalan with or without Total Body Irradiation (TBI) and Autologous Hematopoietic Stem Cell ...", <u>Blood</u> , 100 , 44th Annual Meeting of the American Society of Hematology; Abstract 670, 179a (2002).
	GOECKELER et al., "Samarium-153 Radiotherapeutic Bone Agents", <u>Nucl. Med. Biol.</u> , 13 , 479-482 (1986).

EXAMINER

DATE CONSIDERED


Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Applicati n Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Gr up Art Unit	1614
Examiner Name	Unknown

Sheet 6 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	HASSFJELL et al., "212Bi-DOTMP: An Alpha Particle Emitting Bone-Seeking Agent for Targeted Radiotherapy", <u>Nuclear Medicine and Biology</u> , <u>24</u> , 231-237 (1997).
	HOGAN et al., "Successful Treatment of POEMS Syndrome with Autologous Hematopoietic Progenitor Cell Transplantation", <u>Bone Marrow Transplantation</u> , <u>28</u> , 305-309 (2001).
	HSIA et al., "Preparation of 113mIn-DTPMP Bone Scanning Agent and its Preliminary Clinical Application", <u>Chemical Abstracts</u> , <u>95</u> , 305 (1981).
	JARVIS et al., "Characterization of the Bisphosphonate Recognition Site on Hydroxyapatite Using Radioligand Binding Techniques with [¹⁴ C]Citric Acid", <u>Calcif Tissue Int.</u> , <u>52</u> , 372-377 (1993).
	JOHN et al., "Formulation Development and Stability of the 166Ho-DOTMP for High Level Dosages - A Skeletal Targeted Radiotherapeutic", <u>Journal of Nuclear Medicine</u> , <u>42</u> , Proceedings of the SNM 48th Annual Meeting, No. 1122, 267P (2001).
	KABACHNIK et al., "Synthesis and Acid-Base and Complex-Forming Properties of 1,4,7,10 - Tetrakis (dihydroxyphosphorylmethyl) - 1,4,7,10 - tetraazacyclododecane", <u>Bulletin of the Academy of Sciences of the USSR; Division of Chemical Science</u> , <u>33</u> , 777-782 (1984).
	KABACHNIK et al., "Synthesis and Study of a New Complexone - N,N',N' - Tris- (Dihydroxyphosphorylmethyl) - 1,4,7 - Triazacyclononane", <u>Bulletin of the Academy of Sciences of the USSR; Division of Chemical Science</u> , <u>33</u> , 769-777 (1984).
	KAPLAN et al., "Therapy of Carcinoma of the Prostate Metastatic to Bone with P32 Labeled Condensed Phosphate", <u>The Journal of Nuclear Medicine</u> , <u>1</u> , 1-13 (1960).
	KASI et al., "Ho-166DOTMP: A New Agent for Bone Marrow Ablation", <u>The Journal of Nuclear Medicine</u> , <u>34</u> , Abstract Book, Proceedings of the 40th Annual Meeting, Toronto, Ontario, Canada, Abstract No. 125, 33P (1993).
	KEELING et al., "Yttrium-90-EDTMP: A Radiotherapeutic Agent in the Treatment of Leukaemias", <u>British Journal of Cancer</u> , <u>60</u> , 74-78 (1989).
	KETRING, "153Sm-EDTMP and 186Re-HEDP as Bone Therapeutic Radiopharmaceuticals", <u>Nucl. Med. Biol.</u> , <u>14</u> (3), 223-232 (1987).
	KOHN, "The Current Status of Gene Therapy Using Hematopoietic Stem Cells", <u>Current Opinion in Pediatr.</u> , <u>7</u> , 56-63 (1995).
	KOTHARI et al., "186RE and 188RE Phosphonate Ligands", <u>The Journal of Nuclear Medicine</u> , <u>40</u> , Proceedings of the 46th Annual Meeting, Abstract No. 1015, 228P (1999).
	KRISHNAMURTHY et al., "Tin-117m(4+)DTPA: Pharmacokinetics and Imaging Characteristics in Patients with Metastatic Bone Pain", <u>The Journal of Nuclear Medicine</u> , <u>38</u> , 230-237 (1997).
	KRIVIT et al., "Bone Marrow Transplantation as Effective Treatment of Central Nervous System Disease in Globoid Cell Leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and ...", <u>Curr Opin Neurol</u> , <u>12</u> (2), 167-176 (1999).
	LARSEN et al., "Preliminary Evaluation of a New Radiolabelled Bisphosphonate", <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , <u>XLI</u> , 823-830 (1998).
	LOGAN et al., "Radiation Dose Calculations in Persons Receiving Injection of Samarium-153-EDTMP", <u>J. Nucl. Med.</u> , <u>28</u> , 505-509 (1987).

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Applicati n Number	10/615,484
Filing Date	July 08, 2003
First Nam d Inv nt r	Fritzberg, Alan
Group Art Unit	1614
Examiner Name	Unknown

Sheet 7 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	MA et al., "Indium-113m Labeled Bone Imaging Agents - Animal Experiment and Clinical Application of 113mIn-DTPMP and 113mIn-EDTMP", <u>Chemical Abstracts</u> , 93, 285 (1980).
	MATHIEU et al., "Preparation of Rhenium-186 Labelled EHDP and its Possible Use in the Treatment of Osseous Neoplasms", <u>International Journal of Applied Radiation and Isotopes</u> , 30, 725-727 (1979).
	MCCULLOUGH et al., "99mTc-MDP as a Surrogate Quantitative Imaging Agent for High Dose 166Ho-DOTMP Bone Marrow Ablation Therapy", <u>Society of Nuclear Medicine Proceedings of the 47th Annual Meeting</u> , 41(5), 147P (2000).
	MCCULLOUGH et al., "Non-target Organ Doses in Patients Undergoing Bone Marrow Ablation with Ho-166-DOTMP", <u>The Journal of Nuclear Medicine</u> , 39, No. 5, Abstract Book, Scientific Abstracts of the 45th Annual Meeting of the Society of Nuclear Medicine, Toronto, Ontario, Canada, Abstract No. 838, 186P (1998).
	MCCULLOUGH et al., "Pharmacokinetics and Patient Specific Dosimetry of High Dose 166Ho-DOTMP Therapy Used for Treatment of Breast Cancer Metastatic to Bone", <u>The Journal of Nuclear Medicine: Proceedings of the 46th Annual Meeting</u> , 40, 40P (1999)
	MCCULLOUGH et al., "Preliminary Correlation of Bone Marrow Dose Distributions and Disease Response in Multiple Myeloma Patients Treated with Target Skeletal Radiotherapy", <u>The Journal of Nuclear Medicine, Proceedings of the 47th Annual Meeting</u> , 41(5), Abstract No. 327, 83P (2000).
	MOREAU et al., "Melphalan 220 mg/m2 Followed by Peripheral Blood Stem Cell Transplantation in 27 Patients with Advanced Multiple Myeloma", <u>Bone Marrow Transplant</u> , 23(10), 1003-1006 (1999).
	NAIL, "The Relationship Between the Structure of Aluminum Hydride Gel and Acid Reactivity", <u>Chemical Abstracts</u> , 84, 353 (1976).
	O'MARA et al., "Rare Earth Nuclides as Potential Agents for Skeletal Imaging", <u>The Journal of Nuclear Medicine</u> , 10, 49-51 (1969).
	PARKS et al., "Bone Marrow Transplantation in Dogs After Radio-Ablation with a New Ho-166 Amino Phosphonic Acid Bone-Seeking Agent (DOTMP)", <u>Blood</u> , 82(1), 318-325 (1993).
	PAULSON, "Seattle Leads in Stem Cell Study: Fred Hutchinson Team Explores Options with Autoimmune Project", <u>The Seattle Post-Intelligencer</u> , (1999).
	PODOLOFF et al., "Phase I/II Studies of Holmium-166 DOTMP in Combination with Melphalan with or without Total Body Irradiation as a Preparative Regimen For Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma (MM)", <u>European Journal of Nuclear Medicine</u> , Abstract No. PS-641,1213.
	PODOLOFF et al., "Phase I/II Study of Holmium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma Prior to Bone Marrow Transplantation (BMT)", <u>The Journal of Nuclear Medicine</u> , 35, Abstract Book, Proceedings of the 41st Annual Meeting, Orlando, FL, Abstract No. 139, 37P (1994).
	PODOLOFF, "The Role of Radioisotopes and the Treatment of Solid Tumors", <u>Accomplishments with Medical Isotopes: Advanced Health Care for the 21st Century</u> , Medical Isotopes and the 21st Century (1999).

EXAMINER


DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Complete if Known

Applicati n Number	10/615,484
Filing Dat	July 08, 2003
First Named Inv ntor	Fritzberg, Alan
Group Art Unit	1614
Examiner Name	Unknown

Sheet 8 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	PODOLOFF et al., "Update on the Ho-166 DOTMP Bone Marrow Ablation Trial at U.T.M.D. Anderson Cancer Center", <u>Journal of Nuclear Medicine</u> , <u>37</u> , Supplement: Radiolabeled IUDr, Abstract No.1053, 234P (1996).
	RAJENDRAN et al., "High Dose Holmium-166 DOTMP Myeloablative Treatment for Multiple Myeloma", <u>Journal of Nuclear Medicine</u> , Proceedings of the 47th Annual Meeting, 146P (2000).
	RAJENDRAN et al., "Holmium-166 DOTMP: An Agent with Ideal Physical and Pharmacokinetic Characteristics for Use in Myeloablative Treatment of Multiple Myeloma", <u>Western Regional Soc. Nucl. Med.</u> (2000).
	RAJENDRAN et al., "High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation", <u>J Nucl Med</u> , <u>43</u> , 1383-1390 (2002).
	ROSCH et al., "Radiation Doses of Yttrium-90 Citrate and Yttrium-90 EDTMP as Determined via Analogous Yttrium-86 Complexes and Positron Emission Tomography", <u>European Journal of Nuclear Medicine</u> , <u>23</u> , 958-966 (1996).
	ROSOFF et al., "Distribution and Excretion of Radioactive Rare-Earth Compounds in Mice", <u>International Journal of Applied Radiation and Isotopes</u> , <u>14</u> , 129-135 (1962).
	SALTUS, "Double Transplant's Success May Lead to End of Rejection Drugs", <u>The Seattle Post-Intelligencer</u> , (1999).
	SCHMIDT et al., "89-Sr for the Treatment of Incurable Pain in Patient with Neoplastic Osseous Infiltrations", <u>Int. J. Clin. Pharmacol</u> , <u>9</u> , 199-205 (1974).
	SHERRY, "31P and 23Na NMR Lanthanide Induced Shifts in Axially Symmetric Macrocyclic Phosphonate Complexes", <u>Inorganica Chimica Acta</u> , <u>139</u> , 137-139 (1987).
	SHERRY et al., "Dy(DOTP)5-: A New, Stable, 23Na Shift Reagent", <u>Journal of Magnetic Resonance</u> , <u>76</u> , 528-533 (1988).
	SHIBATA et al., "Selectively Eliminated Blood Monocytes and Splenic Suppressor Macrophages in Mice Depleted of Bone Marrow by Strontium 89", <u>J. Leukocyte Biol.</u> , <u>38</u> , 659-669 (1985).
	SIMON et al., "153Sm-EDTMP, a Potential Therapeutic Bone Agent", Sixth International Symposium on Radiopharmaceutical Chemistry: Abstracts. Boston, June 29-July 3, 1986. Paper 141, 320-322 (1986).
	SPIERS et al., "Mean Skeletal Dose Factors for Beta-particle Emitters in Human Bone. Part II: Surface-seeking Radionuclides", <u>British Journal of Radiology</u> , <u>54</u> , 500-504 (1981).
	SRIVASTAVA et al., "10Ruthenium-97 Labeled Compounds - A New Class of Radiopharmaceuticals", <u>Medical Department, Brookhaven Ntional Lboratory, Upton, NY 11973</u> , 123-133.
	STABIN et al., "Bremsstrahlung Radiation Dose in Yttrium-90 Therapy Applications", <u>J Nucl Med</u> , <u>35</u> , 1377-1380 (1994).
	SUBRAMANIAN et al., "Indium-113m Labeled Polyfunctional Phosphonates as Bone Imaging Agents", <u>Chemical Abstracts</u> , <u>87</u> , 243 (1977).
	SUBRAMANIAN et al., "Indium-113m-Labeled Polyfunctional Phosphonates as Bone-Imaging Agents", <u>Journal of Nuclear Medicine</u> , <u>16</u> , 1080-1084 (1975).

EXAMINER

DATE CONSIDERED


Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Applicant Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1614
Examiner Name	Unknown

Sheet 9 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	SUBRAMANIAN et al., "Localization of new Tc-99m Labeled Diphosphonates in Experimental Bone Lesions", Presented at the 19th International Annual Meeting of the Society of Nuclear Medicine Europe, Bern, Switzerland, September 8-11, 1981 (1981).
	SWAILEM et al., "In vivo Tissue Uptake and Retention of Sn-117m(4+)DTPA in a Human Subject with Metastatic Bone Pain and in Normal Mice", <u>Nuclear Medicine & Biology</u> , 25, 279-287 (1988).
	TANANAEV et al., "Lanthanide Ethylenediametetramethylphosphonates", <u>Chemical Abstracts</u> , 96, 553 (1982).
	THOMAS, "Clinical Trials with Bone Marrow Transplantation", <u>Clinical Trials in Cancer Medicine</u> , Academic Press, Inc., 239-253 (1985).
	THOMAS, "Marrow Transplantation for Malignant Diseases", <u>Journal of Clinical Oncology</u> , 1, 517-531 (1983).
	THOMAS et al., "Marrow Transplantation for Thalassemia", <u>Annals New York Academy of Sciences</u> , 445, 417-427 (1985).
	THOMAS, "MIRD Pamphlet No. 14: A Dynamic Urinary Bladder Model for Radiation Dose Calculations.", <u>Journal of Nuclear Medicine</u> , 33, 783-802 (1992). (Published erratum appears in <u>Journal of Nuclear Medicine</u> , 35, 73 (1994)).
	TURNER et al., "Radiopharmaceutical Therapy of 5T33 Murine Myeloma by Sequential Treatment with Samarium-153 Ethylenediaminetetramethylene Phosphonate, Melphalan, and Bone Marrow Transplantation", <u>Journal of the National Cancer Institute</u> , 85(18), 1508-1513 (1993).
	TURNER et al., "Samarium - 153 EDTMP Therapy of Disseminated Skeletal Metastasis", <u>Eur J. Nucl Med</u> , 15, 784-795 (1989).
	TURNER et al., "Samarium-153 EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation in the C57BL/KalwRij mouse as a model for treatment of multiple myeloma", <u>Australian & New Zealand J of Medicine</u> , 22, 405 (1992).
	TURNER et al., "Samarium-153 EDTMP and melphalan chemoradiotherapy regimen for bonemarrow ablation prior to marrow transplantation: an experimental model in the rat", <u>Nuclear Medicine Communications</u> , 13(5), 321-329 (1992).
	VOLKERT et al., "Characteristics of Tc-99m-Complexes of Large Tetraphosphonates", 1984 Abstract Form for Scientific Exhibits Society of Nuclear Medicine 31st Annual Meeting, Los Angeles, California, June 5-8, 1984.
	WEININGER, "Re-186 HEDP: A Potential Therapeutic Bone Agent", 24(5), Proceedings of the 30th Annual Meeting - Posters, P125.
	WENDT, "An Improved Estimate of Activity in Skull-Like Structures", <u>Journal of Nuclear Medicine</u> , 42, Proceedings of the 48th Annual Meeting, 193P (2001).
	WENDT et al., "Correction of Scatter and Septal Penetration in Ho-166 Images to Enable Narrow Beam Attenuation Correction", <u>Journal of Nuclear Medicine</u> , 43(5), 221P-222P (2002).
	WINSTON, "Radioisotope Therapy in Bone and Joint Disease", <u>Seminars in Nuclear Medicine</u> , 9, 114-120 (1979).
	WISEMAN et al., "Bone Targeted Radioisotope Therapy for Treatment of Multiple Myeloma and Bone Tumors", <u>International Journal of Cancer</u> , 13, Abstract O 109, 104 (2002).

EXAMINER

DATE CONSIDERED


Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many entries as necessary)



Sheet 10 of 10

Complete if Known

Application Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1614
Examiner Name	Unknown

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	WISEMAN et al., "Residual Whole Body ¹⁵³ Samarium Activity Predicts for Successful Autologous Peripheral Blood Progenitor Cell (PBPC) Engraftment Following High Dose ¹⁵³ Samarium Ethylene Diamine Tetramethylene Phosphonate (¹⁵³ Sm-EDTMP) Targeted Radiotherapy", <u>Blood</u> , <u>96</u> , Abstract 1811, 421 (2000).
	YOUNG et al., "High Dose Samarium-153 Ethylenediaminetetramethylene Phosphate (SM-153 EDTMP) in the Treatment of Bone Sarcomas", <u>The Journal of Nuclear Medicine</u> , <u>40(5)</u> , Proceedings of the 46th Annual Meeting, 219P (1999).
	ZEEVAART et al., "Metal-ion Speciation in Blood Plasma Incorporating the Bisphosphonate, 1-hydroxy-4-aminopropylidenediphosphonate (APD), in Therapeutic Radiopharmaceuticals", <u>Journal of Inorganic Biochemistry</u> , <u>73</u> , 265-272 (1999).

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached